Quiet at therapeutic doses, BP-noticeable in lean low-BP individuals. Honest report from the small nootropic / off-label use community + healthy-volunteer arms of clinical trials:

• Acute (single 30-60 mg dose, hours): Onset 30-60 min (well-absorbed, peak plasma 0.6-1.6 hr). Most users report nothing distinguishable. In lean / low-baseline-BP individuals (Dylan-archetype), orthostatic dizziness on standing rapidly is the most-reported acute effect — usually mild, transient, dose-dependent. Mild facial flushing in a fraction of users (vasodilatory). No stim, no sedation, no mood shift.
• Days 1-7: Mild headache day 1-2 in some users (vasodilatory headache pattern; resolves). Some report mild ankle / lower-leg edema (DHP CCB class effect; less prominent with nimodipine than amlodipine). Felt cognitive effect generally absent.
• Weeks 2-6: Cumulative — a subset of users describe "subtle mental clarity," "easier sustained focus," "less mental fatigue late in long workdays," but most describe nothing. Effects are inferential, not felt ("I'm taking it for the calcium-buffering mechanism, not because I notice anything"). Lower-BP-baseline users may notice the BP effect more than the cognitive effect.
• In SAH patients on Rx 60 mg q4h: The BP effect is the dominant subjective — often requires fluid resuscitation or pressor adjustments to maintain MAP for cerebral perfusion. Healthy users at lower doses won't see this magnitude.
• Post-cycle: No withdrawal, no rebound BP elevation. Effects fade over days as plasma clears (half-life ~9 hr for parent drug, but enterohepatic recirculation and active metabolite contribution extend functional duration).
• What it does NOT feel like: Not a stimulant, not a mood enhancer, not a focus drug, not anxiolytic. If a user reports strong felt cognitive effects on nimodipine alone at 30-60 mg/d, suspect placebo or stack effect.

Honest expectation-setting for Dylan: Treat nimodipine like astaxanthin or NBP — quiet insurance with mechanism justification, not a felt drug. The realistic subjective is "I feel basically nothing except occasional orthostatic dizziness if I stand up too fast." Value is in the Ca²⁺-buffering theory of impact prophylaxis, which is unproven in healthy young athletes. If you cycle it for 60-90 days and feel nothing, that's the modal expected experience — judge by absence-of-symptom-progression and (if measurable) NfL trajectory rather than by daily subjective.

• Tolerance buildup: Minimal in receptor sense — DHP binding to L-type channel is straightforward pharmacology, no documented downregulation pathway. Hemodynamic adaptation (mild reflex tachycardia, sodium retention) does occur over weeks; this dampens the BP effect somewhat with chronic use but does not represent loss of CNS Ca²⁺ buffering.
• Recommended cycle: 60-90 days on, 30-60 days off for prophylactic use. Pattern-match to NBP and cerebrolysin cycling logic. Continuous use is clinically established (years of dementia / vascular indications) but for a healthy-young prophylactic user, periodic breaks are conservative and unlikely to cost much mechanistic benefit.
• Reset protocol: No taper required at off-label doses. BP normalizes within days. LFTs (if elevated) normalize within 2-4 weeks.

Synergistic with

• magnesium glycinate / magtein (already in V4) — Mg²⁺ is a physiological Ca²⁺ antagonist at the cellular level (NMDA receptor blockade, vascular smooth muscle, mitochondrial Ca²⁺ uniporter modulation). Combined with nimodipine's voltage-gated Ca²⁺ channel block, the layered Ca²⁺-buffering mechanism is mechanistically clean. Magtein specifically increases brain Mg²⁺. Keep both at full V4 doses during nimodipine cycle.
• agmatine — multi-target neuroprotectant including NMDA antagonism, voltage-gated Ca²⁺ channel modulation, and α2-adrenergic effects. Mechanistically additive with nimodipine for Ca²⁺-overload buffering across pathways.
• cerebrolysin — Different mechanism (peptide-mimetic neurotrophic surge — BDNF/NGF/GDNF), no antagonism, complementary protection. Top-line stack rationale for Dylan if both are pursued — cerebrolysin builds, nimodipine protects.
• 3-n-butylphthalide (NBP) — Multi-target neuroprotectant with mitochondrial preservation (PGC-1α, Mfn1), Nrf2 antioxidant, anti-platelet, anti-neuroinflammatory. NBP and nimodipine target different layers of the impact-injury cascade — NBP downstream (mitochondrial, antioxidant), nimodipine upstream (Ca²⁺ entry). Theoretically additive; no human RCT of combination.
• idebenone — BBB-crossing CoQ10 analog supports mitochondrial electron-transport-chain function during the post-Ca²⁺-flux mitochondrial stress window. Mechanism-complementary.
• citicoline (already in V4) — Membrane phospholipid substrate + cholinergic support. Different mechanism, no antagonism.
• omega-3 / DHA (already in V4 at 2 g) — Anti-inflammatory + neuronal membrane fluidity. Standard neuroprotection foundation, no interaction.
• methylene blue — Mitochondrial electron-cycling support (alternate ETC pathway via complex I bypass). Mechanism-complementary; layered with NBP and idebenone for full mitochondrial coverage.
• astaxanthin (V5 add) — Lipid-soluble Nrf2 activator + mitochondrial membrane antioxidant. No interaction with nimodipine.
• NAC (already in V4 at 1200 mg/d) — Glutathione replenishment, hepatoprotective. Useful given nimodipine's mild hepatic signal.
• PS (phosphatidylserine) (already in V4) — Membrane substrate. Neutral.
• modafinil — No documented interaction. Both are CYP3A4 substrates; modafinil is a mild CYP3A4 inducer which would modestly reduce nimodipine plasma levels (the opposite of the inhibitor concern). Not a hard interaction; monitor BP if both are running.

Avoid stacking with

• Strong CYP3A4 inhibitors — ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice (regular intake). Markedly increase nimodipine plasma exposure → hypotension. None are in Dylan's stack except occasional dietary grapefruit (avoid on dosing days).
• Other antihypertensives — ACE inhibitors, ARBs, other CCBs, beta-blockers, diuretics. Additive hypotension. Not relevant for Dylan.
• Strong CYP3A4 inducers — rifampicin, St. John's wort, carbamazepine, phenytoin. Reduce nimodipine plasma levels meaningfully (rifampicin can drop AUC by 80%+) — efficacy compromise. None in Dylan's stack.
• Alcohol heavy load — additive vasodilation + dehydration → orthostatic. Dylan is alcohol-zero.
• High-dose niacin (>500 mg flush form) — additive vasodilation, additive flushing. Not relevant.
• Sildenafil / tadalafil / vardenafil — additive vasodilation. Relevant if Dylan ever uses; manageable with timing separation.

Neutral / safe co-administration

• All V4 daily core supplements (Mg, D3+K2, magnesium threonate, theanine, glycine/tryptophan, beta-alanine, vitamin C, rhodiola, NAC, citicoline, curcumin phytosome, omega-3, PS, creatine)
• Modafinil at 100 mg AM (mild CYP3A4 inducer, modest theoretical concern — monitor BP)
• Bromantane, Adamax/Semax, ALCAR, taurine, apigenin — no documented interactions
• BPC-157, TB-500 — no interactions
• Selegiline at 1-2.5 mg/d — no documented interaction (sub-MAO-A threshold)
• Cerebrolysin (IM peptide) — no interaction; complementary mechanism
• L-tryptophan, glycine — no interaction

• CYP3A4 substrate (extensively). Nimodipine has a relatively high first-pass effect and is metabolized predominantly by CYP3A4 to inactive metabolites. Bioavailability is ~13% (large interindividual variability — 4-30%). Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) can increase AUC 2-7×, producing hypotension. Strong inducers (rifampicin) reduce AUC by 80-90% — efficacy compromise. For Dylan: practical concern is grapefruit juice (avoid on dosing days) and any future antifungal / antiretroviral / antibiotic course.
• Other CCBs. Additive Ca²⁺-channel blockade → significant hypotension. Not relevant.
• Beta-blockers. Additive negative inotropy + bradycardia + hypotension. Not relevant.
• ACE inhibitors / ARBs / diuretics. Additive hypotension. Not relevant.
• Phenobarbital, carbamazepine, phenytoin. CYP3A4 inducers — reduce nimodipine efficacy. Not relevant.
• Sildenafil / tadalafil. Additive vasodilation. Manageable with timing.
• Hormonal contraceptives. Mild CYP3A4 induction by some progestins could modestly affect nimodipine; clinically minor. Not relevant.
• Caffeine, nicotine, alcohol. Caffeine no interaction. Alcohol additive vasodilation (Dylan zero). Nicotine no interaction.
• Statins (simvastatin, atorvastatin). Both are CYP3A4 substrates — competitive metabolism, minor effect on each. Not relevant for Dylan.
• Lithium. Possible additive neurotoxicity reported in case reports; theoretical only. Not relevant.

Nimodipine pharmacogenomics is moderately characterized for the metabolic side (CYP3A4) but less so for the target side (CACNA1C / CACNA1D).

• *CYP3A4 polymorphisms (CYP3A4*22, 22 carriers ~5% Europeans). Reduced enzymatic activity → higher nimodipine exposure → more hypotension at standard doses. Worth checking on Dylan's 23andMe (June 2026 data window). If *22 carrier, start at 15-30 mg dose.
• CYP3A5 polymorphisms (CYP3A5*3, *3/*3 = non-expressor, ~85% Europeans). Most Europeans are CYP3A5 non-expressors, so CYP3A4 dominates. Less clinically relevant for Dylan's ancestry.
• CACNA1C (Cav1.2 α-subunit) polymorphisms. rs1006737 (the bipolar / schizophrenia GWAS variant) and others affect channel expression / function. Theoretical: carriers of risk variants might have differential response to L-type channel blockade. No clinical pharmacogenomics study of nimodipine response stratified by CACNA1C genotype. Worth pulling on 23andMe / Promethease for exploratory interest.
• CACNA1D (Cav1.3 α-subunit) polymorphisms. Less GWAS-validated; affects neuronal Cav1.3 (more involved in pacemaker function and certain neurons).
• APOE ε4. Increases dementia risk; theoretical greater benefit from neuroprotection. Not directly studied for nimodipine. Worth checking on 23andMe (informs broader strategy).
• Polymorphisms in efflux transporters (ABCB1 / P-glycoprotein). P-gp affects BBB drug efflux; nimodipine is a P-gp substrate. ABCB1 C3435T variant carriers may have higher CNS exposure. Theoretical only.

Action item post-23andMe: Pull CYP3A4, CYP3A5, CACNA1C, CACNA1D, ABCB1, APOE variants. None will change the decision to trial nimodipine, but a CYP3A4*22 finding would push starting dose down to 15-30 mg, and CACNA1C risk-variant carriage would slightly reinforce the mechanism rationale.

Cost math for Dylan's proposed protocol:

• Pilot cycle: 30 mg AM × 14 days = 14 caps. Indian pharmacy 90-cap pack ~$30-50 → ~$5-10 used in pilot.
• Pilot cycle 2: 30 mg BID × 30 days = 60 caps. Indian pharmacy ~$30-50 for one 90-cap pack covers it.
• Maintenance cycled: 30 mg BID × 60-90 days, 30-60 days off → ~$20-40/month effective cost averaged over the cycle.
• US Rx via telehealth (if achievable): $15-50/month, lower cost but indication friction. The off-label psychiatric (treatment-resistant bipolar) telehealth pitch is a legitimate path if Dylan ever wanted it; the cognitive / impact-prophylaxis pitch will not get an Rx.
• Recommendation: Indian pharmacy gray-import for Dylan's use case. Same logistics as modafinil, well-trodden path. Verify with first small order.

Quality verification:

• Indian pharmacy: standard checks — packaging consistency, lot/expiry, manufacturer (Bayer-generic vs Indian-domestic generic). Bayer Nimotop is the gold-standard brand; Indian generics (Nimocer, Vasotop) are clinically used and reliable.
• Research-chem: COA from vendor — HPLC ≥98%, residual solvent within spec.

Supply note: US generic nimodipine has had multiple supply disruptions 2018-2024 (Pfizer, Heritage manufacturers). FDA Drug Shortages list periodically includes it. Indian sourcing is more reliable for chronic use over years.

Baseline (before starting)

• CBC, CMP — full liver panel (ALT, AST, ALP, GGT, total bilirubin, albumin), kidney function (Cr, BUN, eGFR), electrolytes (already planned for June 2026)
• Lipid panel, hsCRP, IL-6 — baseline inflammation/vascular markers (already planned)
• Resting BP and HR — baseline measured at home over 7 days, AM + PM, same arm. Document mean baseline. Critical for Dylan given lean physique + MMA conditioning likely produces lower-than-population resting BP.
• Orthostatic BP — supine BP, then 1-min and 3-min standing BP. Baseline orthostatic delta. If already orthostatic at baseline (>20 mmHg systolic drop), nimodipine adds cumulative risk.
• EKG (baseline) — particularly if ever pursuing higher doses or if any atypical cardiac history.
• Serum NfL — concussion / axonal damage biomarker; the most informative biomarker for Dylan's MMA brain-protection thesis. Order via specialty lab (Quanterix Simoa platform).
• GFAP, S100B — astrocyte injury biomarkers; complementary to NfL.
• Cognitive baseline — CNS Vital Signs / Cambridge Brain Sciences battery; document executive function, working memory, processing speed, reaction time.
• 23andMe pull (already ordered): CYP3A4, CYP3A5, CACNA1C, CACNA1D, ABCB1, APOE — informs metabolism + theoretical response.

During use

• BP monitoring at home: daily for first 7 days, then 2-3×/week through week 4, then weekly during steady-state cycle. Document AM + PM, supine + standing.
• Week 0, 4: ALT/AST. Stop if ALT >3× ULN.
• Subjective log: energy, cognition, mood, sleep, dizziness, headache, edema, GI symptoms, any rash. Daily log for first 2 weeks then weekly.
• Resting HR weekly — mild reflex tachycardia is possible at higher doses; trend over time.
• Mid-cycle hsCRP (week 4) — track inflammation response (optional).

Post-cycle (if cycled)

• Week 4 post-cycle: Repeat BP (should be at baseline) + LFTs (should be normal).
• Week 6-8 post-cycle: Repeat cognitive battery; compare to pre-cycle.
• 6-month: NfL trajectory if multi-cycle protocol — track downward trend or stable across cycles vs sparring exposure.